2017 · Analytical and bioanalytical chemistry · paywalled
Comparison of paper spray mass spectrometry analysis of dried blood spots from devices used for in-field collection of clinical samples
Yannell et al.
The finding, in our words
Four dried blood spot collection devices were compared using paper spray mass spectrometry for rapid quantification of imatinib and N-desmethyl-imatinib; several novel devices performed similarly to traditional manual methods, and clinical samples from a remote location were successfully analysed, supporting decentralised therapeutic drug monitoring in oncology.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
In AML and CLL, 91% of VAMS venetoclax results fell within 20% of plasma after individualised haematocrit correction; in home sampling, 18 of 21 patients self-sampled independently and 76% of returned samples were analysable, which shows home microsampling is workable, though the authors ask for multicentre validation.
A review of 39 studies found that dried blood spot and volumetric absorptive microsampling show promising results for therapeutic drug monitoring of oral targeted anticancer drugs. The authors state that external validation remains crucial to confirm reliability, citing haematocrit effects and sample stability as key challenges.
A review of dried blood microsampling for tyrosine kinase inhibitor monitoring, covering the analytical and clinical requirements for moving oral cancer-drug TDM out of hospital.
Dried blood spot sampling showed good agreement with whole blood for measuring everolimus in cancer patients, with ninety percent of samples demonstrating acceptable prediction error and low bias. This enables home-based therapeutic drug monitoring, allowing clinicians to individualise dosing without requiring patient visits.
This review found that volumetric microsampling devices, such as Mitra, HemaPEN, HemaXis DB10, and Tasso-M20, overcome haematocrit bias, whilst Telimmune plasma separation cards enable direct plasma collection without centrifugation. These technologies support patient-centric, decentralised sampling, though the authors note that clinical validation remains limited across different drugs and patient populations.